8 May 2019
Drax Group plc
("Drax" or "the Company")
Symbol: DRX
Notification of Transactions of Directors,
Persons Discharging Managerial Responsibility or Connected Persons
Andy Skelton has notified the Company that on 7 May 2019 he purchased 15,000 ordinary shares in the Company at a price of 331.316 pence per share. Following the transaction, Mr Skelton's total shareholding in the Company is 15,000 ordinary shares.
The information below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation 596/2014 notification and is in respect of ordinary shares of 11 16/29 pence each in the share capital of the Company of which there were 409,387,309 shares in issue at the time of the dealing.
|
Details of PDMR / person closely associated with them ("PCA") |
|||||
|
Name |
Andy Skelton |
||||
|
Reason for the notification |
|||||
|
Position / status |
CFO, Drax Group plc |
||||
|
Initial notification / amendment |
Initial Notification |
||||
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
Name |
Drax Group plc |
||||
|
LEI |
549300YPSNTXR4ZHSR98 |
||||
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
Description of the financial instrument Identification code |
Ordinary shares of 11 16/29 pence GB00B1VNSX38 |
||||
|
Nature of the transaction |
Purchase of shares |
||||
|
Price(s) and volume(s) |
|
||||
|
Aggregated information - Aggregated volume - Price |
15,000
£49,697.40 |
||||
|
Date of the transaction |
2019.05.07 |
||||
|
Place of the transaction |
London Stock Exchange |
||||
--ENDS--
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
